Panagiotis Repoussis

Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide

Meletios Α. Dimopoulos, Athanasios K. Anagnostopoulos, Marie‐Christine Kyrtsonis et al. · Journal of Clinical Oncology · 2007 · 277 citations · Full text

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Andreas Katsigiannis et al. · The Oncologist · 2012 · 122 citations · Full text

Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicentre study

Helen Giamarellou, Evangelos J. Giamarellos‐Bourboulis, Panagiotis Repoussis et al. · Clinical Microbiology and Infection · 2004 · 96 citations · Full text

Diagnostic Criterion, Potential Use, Diagnosis +3

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma

Meletios Α. Dimopoulos, Anastasia Pouli, Konstantinos Zervas et al. · Annals of Oncology · 2003 · 77 citations · Full text

Hematological Malignancy, Oncology, Hematology +8

Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)

Efstathios Kastritis, Marie‐Christine Kyrtsonis, Evdoxia Hadjiharissi et al. · Leukemia Research · 2010 · 59 citations

Biomarker (Medicine), Prognostic Biomarkers, Prognosis +7